Türeci Ö - Search Results

1

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults.

Murdoch L, Quan K, Baber JA, Ho AWY, Zhang Y, Xu X, Lu C, Cooper D, Koury K, Lockhart SP, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Kitchin N; C4591030 Clinical Trial Group. Murdoch L, et al. Among authors: tureci o. Infect Dis Ther. 2023 Sep;12(9):2241-2258. doi: 10.1007/s40121-023-00863-5. Epub 2023 Sep 12. Infect Dis Ther. 2023. PMID: 37698774 Free PMC article.

2

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

3

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: tureci o. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

4

Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.

Koslowski M, Türeci O, Huber C, Sahin U. Koslowski M, et al. Among authors: tureci o. Mol Cancer. 2009 Sep 25;8:77. doi: 10.1186/1476-4598-8-77. Mol Cancer. 2009. PMID: 19781065 Free PMC article.

5

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.

Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. Kuhn AN, et al. Among authors: tureci o. RNA Biol. 2011 Jan-Feb;8(1):35-43. doi: 10.4161/rna.8.1.13767. Epub 2011 Jan 1. RNA Biol. 2011. PMID: 21289486

6

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

7

mRNA as a versatile tool for exogenous protein expression.

Kuhn AN, Beiβert T, Simon P, Vallazza B, Buck J, Davies BP, Tureci O, Sahin U. Kuhn AN, et al. Among authors: tureci o. Curr Gene Ther. 2012 Oct;12(5):347-61. doi: 10.2174/156652312802762536. Curr Gene Ther. 2012. PMID: 22827224 Review.

8

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U. Kreiter S, et al. Among authors: tureci o. Oncoimmunology. 2012 Aug 1;1(5):768-769. doi: 10.4161/onci.19727. Oncoimmunology. 2012. PMID: 22934277 Free PMC article.

9

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. Diken M, et al. Among authors: tureci o. Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Methods Mol Biol. 2013. PMID: 23296938 Review.

10

Antigen identification using SEREX.

Sahin U, Türeci O. Sahin U, et al. Among authors: tureci o. Methods Mol Biol. 2013;1061:59-77. doi: 10.1007/978-1-62703-589-7_3. Methods Mol Biol. 2013. PMID: 23963930

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page